The use of biomineralization that regulates cellular functions has emerged as a potential therapeutic tool.
Introduction
Biomineralization is an essential physiological process, which efficiently utilizes inorganic elements that are available in body uids.
1 It involves homeostasis of bones and skeletal tissues for suitable mechanical functions and internal supports through the cell-mediated deposition and resorption of inorganic substances. 2 In addition, sequestration and secretion of intracellular mineral deposits (e.g. amorphous calcium phosphate) contribute to the regulation of cellular ion homeostasis, fate, and signaling roles. 3, 4 Generally, these biomineralization processes are tightly regulated by modular genetic mechanisms and physiological processes. Therefore, a pharmacological approach for regulating biomineralization could provide a new tool for controlling cellular functions and would have potential therapeutic applications.
Recently, the potential use of extracellular biomineralization (e.g. calcication and silicication) in vitro and in vivo has been demonstrated in cell and cancer therapies.
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However, abnormal extracellular mineral deposits can cause cellular damage to normal cells near the mineral nucleation sites, diffusion barriers for biological molecules, and the loss of cellular susceptibility to environmental changes. 5 In this regard, incorporating intracellular targeting strategies into the biomineralization system would be benecial due to the targeted delivery capability for desired therapeutics, reducing side effects. 9 A number of particular subcellular compartments including the endosome, endoplasmic reticulum, Golgi complex, mitochondria, and nucleus have been studied for enhancing anticancer efficiency.
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Of these organelles, the targeting of mitochondria has offered a promising strategy to improve chemotherapy efficiency by reducing toxic side effects. [11] [12] [13] Specically, conjugation of the drug to triphenylphosphonium (TPP), a lipophilic cation, enables more than $10 times greater accumulation of the drug in the mitochondria of cancer cells than in those of normal cells as the mitochondrial membrane potential of cancer cells ($À220 mV) is more negative than that of normal cells ($À160 mV).
14, 15 The conjugation of TPP with bioactive molecules (e.g. small molecules and peptides) thus would be a promising approach to target and disrupt the mitochondria of cancer cells, enhancing the efficacy of cancer chemotherapy. [16] [17] [18] Recently, we reported that the supramolecular polymerization of dipeptides inside the mitochondria induced the dysfunction of mitochondria by disrupting the membrane, resulting in the selective apoptosis of cancer cells. Due to the more negative mitochondrial membrane potentials in cancer cells compared to in normal cells, the TPPconjugated molecules highly accumulated in the cancer cells and induced the self-assembled structures. 17 Based on these previous reports and our observation, we hypothesized that biomineralization inside the mitochondria also would induce physical damage to the mitochondria and have a selective anticancer effect.
Here, we report a mitochondria-targeting biomineralization system featuring TPP-conjugated trialkoxysilanes. The use of the trialkoxysilane takes advantage of environment-responsive silicication specic to the basic conditions of the mitochondrial matrix ($pH 8). It induced the formation of silica particles that could act as mitochondrial dysfunction agents. Additionally, owing to the mitochondria targeting ability of TPP, the TPPconjugated trialkoxysilanes exhibited preferential accumulation in the cancer cells over the normal cells. The silica particles depolarized and disrupted the mitochondrial membrane, generating reactive oxygen species (ROS). This further induced the dysfunction of mitochondria and activated apoptotic pathways, resulting in the anti-tumor effect in vitro and in vivo. These results showed that intra-mitochondrial biomineralization could provide a new tool for regulating cellular functions and therefore could have potential therapeutic applications (Scheme 1).
Results and discussion
Triethoxypropylsilane-TPP (1) was synthesized via a dicyclohexylcarbodiimide (DCC) coupling reaction and puried by size exclusion chromatography (ESI Scheme S1 †). We hypothesized that the concentration of the trialkoxysilane is vital for formation of large silsesquioxane particles. To clarify the concentration dependence of the silicication, we rst monitored the light scattering intensity of 1 dissolved in pH 8 ammonium buffer solution at different concentrations (1, 10, and 40 mM). The intensity increased considerably at 40 mM within 10 h. The 10 mM solution showed a slow intensity increase over 72 h, whereas there was no signicant increase at the lower concentration (1 mM) (Fig. 1B) . This suggests that 1 requires a critical concentration ($5 mM) for the formation of relatively large silica particles (Fig. S10 †) . In contrast, trimethylpropylsilane-TPP (2) showed no concentration-dependent behavior with respect to light scattering (Fig. S10 †) . Therefore, 1 exhibited formation of silsesquioxanes via hydrolytic condensation, while for the control molecule, 2, silicication did not occur. This was further conrmed by transmission electron microscopy (TEM) ( Fig. 1C and D) . While the images showed small silica particles of several hundred nanometers in diameter in the case of the low concentration solution (1 mM), larger silica particles ranging from hundreds of nanometers to several micrometers in diameter were found in the high concentration solution (40 mM). Interestingly, the light scattering of 1 at pH 7.4 showed little increase even at a high concentration. It is known that the hydrolytic condensation of trialkoxysilanes can be catalyzed by both basic and acidic conditions, whereas it is stable under neutral and low ionic conditions. [19] [20] [21] Thus, a high enough critical concentration and an acidic/basic environment are necessary for the effective silicication of trialkoxysilane.
The lipophilic cation (TPP) moiety can drive signicantly high accumulation of trialkoxysilanes in cancerous mitochondria due to their higher negative membrane potentials than those of normal cells. 15, 16, 22 This leads to the critical concentration and suitable conditions for silicication within the mitochondrial basic environment ($pH 8). 19, 20 To assess intramitochondrial silicication, TEM experiments for SCC7 cells, a squamous cell carcinoma cell line, treated with 1 (at 10 mM for 72 h) were conducted. As shown in Fig. 2A , the cellular morphology was disrupted and normal mitochondria were not observed. Instead, large particles of $1 mm in diameter were observed, which might indicate the occurrence of silicication within mitochondria. In contrast, the mitochondria of HEK293T cells, a normal kidney cell line, remained unaffected by the same 1 treatment. To further investigate mitochondrial dysfunction, we observed the mitochondrial morphology through uorescence microscopy. The elongated healthy mitochondria showed severe morphological damage with fragmentation when incubated with 1 (Fig. 2B) . However, the Scheme 1 Representation of the selective accumulation of trialkoxysilane-TPP in cancerous mitochondria. This leads to mitochondriaspecific silicification to form biominerals that induce cellular apoptosis. mitochondria remained healthy when incubated with 2. Using ImageJ soware with instructor direction, 27 we could identify mitochondrial fragmentation via edge detection and the average area/perimeter ratio of mitochondria, which is an index of interconnectivity. The index of interconnectivity was calculated as 0.2182 and 0.00637 in SCC7 cells treated with PBS and molecule 1, respectively, indicating signicant mitochondrial fragmentation (Fig. S19 †) . Depolarization of the mitochondrial membrane was observed using tetramethylrhodamine methyl ester (TMRM), which shows red uorescence that vanishes on membrane depolarization. 23 Red uorescence was observed in both TMRM-labeled SCC7 cells and HEK293T cells treated with 1 aer 1 h of incubation. The uorescence faded in SCC7 cells within 5 h, whereas HEK293T cells still showed bright red uorescence aer 5 h of incubation (Fig. 2C) . The confocal images revealed that 1 can selectively depolarize the mitochondrial membrane. In contrast, the uorescence in cancer cells treated with 2 was detected even aer 5 h (Fig. S12 †) .
We speculated that concentration-dependent biomineralization would give rise to selective mitochondrial dysfunction in cancer cells. The accumulation of 1 inside the mitochondria of cancer cells induces silicication, leading to mitochondrial dysfunction, while the concentration in the mitochondria of normal cells might not be sufficient for silicication occurrence. To investigate this, we measured the amount of Si per cell using inductively coupled plasma-optical emission spectrometry (ICP-OES). When both cell types were incubated with 25 mM 1 for 48 h, ICP-OES analysis showed that 0.408 pg per cell and 0.056 pg per cell of silica accumulated in the SCC7 cell and the HEK293T cell, respectively (Fig. 2D) . This indicated that the concentration of 1 in the mitochondria of cancer cells was 7-fold greater than that in the mitochondria of normal cells (Fig. S11 †) . This was mainly due to the difference of mitochondrial membrane potential between normal and cancer cells. 16 Similarly to the concentration-dependent formation of silica particles in the bulk solution (Fig. 1C and D) , signicantly larger silica particles were formed in the mitochondria of cancer cells due to the high accumulation of 1. In contrast, the low concentration of 1 in the mitochondria of normal cells might not be sufficient to form large silica particles. This result was consistent with the TEM measurements ( Fig. 2A) . Additionally, the cellular uptake of 2 was found to be about 2-fold less efficient than that of 1 (Fig. S11 †) , suggesting that the formation of silica particles accelerates the accumulation of 1 unlike monomeric TPP 2. 17 As a consequence, these results revealed that silicication occurring at a high concentration has an important damaging effect on the mitochondria of cancer cells. Depolarization of the mitochondrial membrane leads to oxidative stress, which generates mitochondrial reactive oxygen species (ROS). Excessive production of ROS causes damage in mitochondrial DNA, membranes and proteins. Confocal analysis using dihydroethidium (DHE), which emits bright red uorescence in response to elevated levels of ROS, showed strong red uorescence in SCC7 cells aer 5 h of incubation with 1 (Fig. 2E) . In contrast, the red uorescence was not observed in HEK293T cells (Fig S14 †) . Furthermore, staining with MitoSOX Red, which also emits red uorescence in the presence of ROS, showed bright red uorescence (Fig. S13 †) indicative of mitochondrial ROS generation. However, when incubating DHE labeled SCC7 cells with 2, red uorescence was not observed aer 5 h of incubation (Fig. S15 †) , implying that biomineralization induces mitochondrial dysfunction rather than the molecule itself. To conrm mitochondrial dysfunction, we analyzed the cellular ATP level as mitochondrial dysfunction would affect ATP production. 16 The ATP activity in SCC7 cells treated with 1 decreased to 20% aer 72 h of incubation (Fig S20 †) .
Considering the cancer selectivity of mitochondrial dysfunction by 1, we expect that this will be a cancer specic therapy since mitochondrial dysfunction induces cellular death. We analyzed whether specic silicication could affect cell viability. Aer 24 h of incubation, 1 exhibited low toxicity even at high concentrations (up to 40 mM). However, signicant cellular toxicity was observed with a half maximal inhibitory concentration (IC 50 ) of 3-4 mM aer 72 h of incubation (Fig. 3A) . It may be considered that this time-dependent toxicity against SCC7 cells is due to the requirement for a period over which silicication can occur. In contrast, 1 showed low toxicity towards the normal cells even aer 72 h, suggesting that 1 could be used in an anticancer therapeutic approach (Fig. 3B) . The cell viability results were further conrmed by propidium iodide (PI) and FITC-annexin V staining analysis. 24 These showed the presence of annexin V but not PI in SCC7 cells treated with 25 mM 1 for 24 h, (Fig. S16 †) , indicative of an early apoptotic phase. Fluorescence-activated cell sorting (FACS) was used to quantitatively analyze uorescence of FITC-annexin V/PI staining. The FACS results showed that the cells lapsed into late apoptotic stages within 48 h (Fig. 3C) . As a consequence, 1 produced specic silicication inside the mitochondria of cancer cells, inducing mitochondrial dysfunction that resulted in apoptosis. In contrast, 2 had lower toxicity towards both cancer and normal cells (Fig. S22 †) . As another control, a TPP molecule without the silane part ((3-bromopropyl)triphenylphosphonium) also showed low toxicity towards cancer cells even aer 72 h of incubation, indicating that the silicication is essential to induce apoptosis of cancer cells (Fig. S23 †) .
To investigate this system further, our molecular design was extended to triethoxysilane-Mor (3) targeting lysosomes (Scheme S2 †). 25 We wondered whether silicication in the lysosome would also be efficient, because the lysosome is much smaller so the local concentration of 3 could be signicantly increased and low pH (pH 4-5) could rapidly catalyze the silicication. As a lysosome is a crucial organelle containing numerous hydrolytic enzymes, dysfunction of the lysosome could lead to cellular toxicity. However, lysosome targeting molecule 3 showed low toxicity towards cancer cells (Fig. S24 †) . We considered that the insignicant lysosomal stress caused by exocytosis that could induce the escape of silica particles might result in the reduced extent of lysosomal dysfunction.
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Mitochondria are important organelles that are associated with cellular function, ATP production, and cell death mechanisms. It is considered that mitochondria dysfunction in cells can induce apoptosis. Dysfunction of mitochondria leads to the release of cytochrome c, which is a biomarker of apoptosis. Thus, incorporating mitochondria targeting strategies into the biomineralization system would be benecial due to the targeted delivery capability for desired therapeutics, reducing side effects. To investigate whether mitochondria targeting biomineralization shows an anticancer effect against various cancer cell lines (SCC7, MDA-MB-468, HeLa, KB and PC3 MDAMB-231), we analyzed the cell viability of these cancer cell lines. We expected that intra-mitochondrial biomineralization could also be used with other cancer cell lines. The toxicity of 1 towards a variety of cancer cell lines, such as MDA-MB-468 cells and HeLa cells, was analyzed and they showed an IC 50 of 10-20 mM (Fig. S17, S18 and S21A-F †) . Furthermore, we considered that the targeting mitochondria strategy could be a promising approach to overcome drug resistance caused by efflux proteins in cellular membranes. 1 had high toxicity against the drug resistant cell lines SNU-620-ADR cells and MCF7/ADR cells, with an IC 50 of about 21 mM (Fig. S21G and H †). These results suggested that mitochondrial dysfunction by biomineralization could be a good method to overcome multidrug resistance. In contrast, a low toxicity was observed in the normal cells NIH-3T3. This was a result of the lower accumulation of 1 (Fig. S21I †) . Overall, these results indicated that selective intramitochondrial silicication has an anti-cancer effect (Table 1) .
Finally, to validate the silicication at tissue level, in vivo evaluations were performed. Balb/C nude mice (purchased from Orientbio, Korea) weighing $20 g (7 weeks old, female) were kept in cages and fed periodically following the UNIST-IACUC guidelines for the care and use of laboratory animals. All animal experiments were conducted under protocols approved by the Institutional Animal Care and Use Committee of the Ulsan National Institute of Science and Technology (UNIST). Aer the establishment of tumors, mice were treated with saline, 2, and 1 by peritumoral injection once every 3 days for 16 days (day 0, 3, 6, 9 and 12). A total of 12 mice were allocated to three groups treated with 1 (50 mg kg À1 in PBS), 2 (50 mg kg
À1
in PBS) and saline as control. ICP-OES analysis showed that of silica accumulated in the saline, 2 and 1 groups, respectively (Fig. S25 †) . These in vivo tissue results were consistent with the cell-level in vitro results. In addition, ex vivo data showed that silicon accumulated well inside the tumors, compared with normal tissue (Fig. S25 †) . Given the targeting silicication, we evaluated the in vivo therapeutic efficiency of the silicication in mice bearing SCC7 tumors. As shown in Fig. 4A -C, treatment with 2 showed comparable tumor growth inhibition with that in the control. In contrast, tumor growth was suppressed by a formulation of 1, and H&E staining showed tumor remission aer triethoxysilane 1 treatment, suggesting that the silicica-tion has a signicant anticancer effect (Fig. 4E) . Additionally, the normal organs remained healthy aer triethoxysilane treatment (Fig S26 †) . Meanwhile, a noticeable change of body weight and even of body weight with tumor weight subtracted was not observed in either group, indicating that the silicica-tion was biologically friendly (Fig. 4D and S27 †) . Furthermore, to investigate the fate of 1 in vivo, we analyzed the amount of silicon in urine samples, which were collected into separate tubes at 4 h, 12 h, 24 h and 72 h aer administration of 1 (50 mg kg
). ICP-OES analysis showed that 7.6 mg mL À1 of silicon was excreted into urine at 4 h. However, an insignicant amount of silicon was observed in urine collected aer 12 h, suggesting that 1 would be excreted into urine within 12 h (Fig S28 †) .
Conclusions
In summary, we developed a mitochondria-targeting silicica-tion system using 1 that selectively eliminates cancer cells. 1 produced concentration dependent silicication under acidic/ basic conditions, revealing that effective silicication occurs only at high concentrations. The lipophilic cation (TPP) moiety of this system drives the accumulation of 1 inside the mitochondria, providing the effective conditions for silicica-tion. This specic silicication induces the depolarization of the mitochondrial membrane, disrupting it and generating ROS. As mitochondria are the power sources of cells, the dysfunction of mitochondria leads to apoptosis in cancer cells. At the in vivo level, this system showed inhibition of tumor growth. Thus, our novel approach through organelle-specic biomineralization provides a new strategy for the treatment of cancer cells.
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